کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5666647 | 1591535 | 2017 | 7 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity](/preview/png/5666647.png)
- Nef protein is an attractive target in therapeutic HIV vaccine development.
- The immunogenicity of antigens can be increased by molecular adjuvants.
- Hsp27 interacts with TLRs and induces the release of pro-inflammatory cytokines.
- Hsp27-Nef fusion protein could significantly elicit the effective immune responses.
- Hp91 peptide combined with Nef significantly enhances Nef-specific T cell responses.
Novel vaccine modalities have been designed to improve the efficiency of vaccines against HIV infections. In this way, the HIV-1 Nef protein has been known as an attractive antigenic candidate in therapeutic vaccine development. Moreover, the endogenous adjuvants such as heat shock proteins (HSPs) and high mobility group box 1 protein (HMGB1) have been suggested effectively to induce antigen-specific humoral and cellular immune responses. In this study, different Nef DNA and protein constructs were produced in eukaryotic and prokaryotic expression systems, and their immunostimulatory properties were evaluated using small heat shock protein 27 (Hsp27) and the HMGB1-derived peptide (Hp91) in a mouse model. Generally, our results indicated that the Hsp27-Nef fusion DNA or protein could significantly elicit higher humoral and cellular immune responses than Nef DNA or protein, respectively. Analysis of the immune responses demonstrated that the Hsp27-Nef fusion protein, and also the mixture of Nef and Hp91 significantly enhanced the Nef-specific T cell responses. Indeed, these regimens induced high levels of IgG2a and IFN-γ directed toward Th1 responses and also Granzyme B secretion as compared to other immunization strategies. The immunostimulatory properties of Freund's adjuvant were significantly less than Hsp27 and Hp91 peptide in various immunization strategies. These findings showed that the use of Hsp27 and Hp91 in protein strategy could improve HIV-1 Nef-specific B- and T-cell immune responses, and also represent a promising HIV-1 vaccine candidate in future.
Journal: Immunology Letters - Volume 191, November 2017, Pages 16-22